Anti-Complement Factor B (CFB) Rabbit Polyclonal Antibody for WB, ELISA - P00751

Core Product Specifications and Parameters

Biological Background: Complement Factor B Function and Localization

• Complement factor B (CFB) is the precursor of the catalytic component of the alternative complement pathway C3 and C5 convertase complexes, playing a key role in innate immunity and amplification of all complement activation routes. Related references: PMID:3638964 / PMID:624565 / PMID:6554279
• CFB is cleaved by complement factor D (CFD) to generate the Ba (regulatory) and Bb (catalytic serine protease) chains; the Bb fragment serves as the serine protease component of the C3 and C5 convertases. Related references: PMID:6769474 / PMID:9748277
• Together with complement C3b, the Bb fragment forms the alternative pathway C3 convertase (C3bBb), which cleaves C3 into the anaphylatoxin C3a and the opsonin C3b. Related references: PMID:3638964 / PMID:624565 / PMID:6554279
• Upon binding of an additional C3b molecule, the C3 convertase becomes the C5 convertase (C3bBbC3b), which cleaves C5 into C5a and C5b, initiating the terminal membrane attack complex formation. Related references: PMID:30643019 / PMID:624565 / PMID:6554279
• CFB also promotes preactivated B-lymphocyte proliferation and differentiation, monocyte spreading, lymphocyte blastogenesis, and erythrocyte lysis, linking innate and adaptive immunity.
• It is a secreted glycoprotein also found on cell surfaces, with multiple post-translational modifications including proteolytic cleavage, glycation, and disulfide bond formation; alternative splicing yields additional isoforms.
• Mutations in CFB are associated with complement-mediated diseases such as atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD), underscoring its clinical relevance in diagnostic settings.

Experimental Guidance and Technical Tips

• The immunogen (a.a. 80-420) spans both the Ba regulatory domain and the Bb catalytic serine protease domain, including the factor D cleavage site, making the antibody potentially reactive with the full-length protein and the Bb fragment in WB under reducing and non-reducing conditions.
• For WB, a band of approximately 86 kDa is expected for the full-length CFB in human, mouse, and rat samples; consider using appropriate positive controls, such as serum or plasma, which are rich in complement factors.
• In ELISA applications, this polyclonal antibody may be used for capture or detection of CFB; optimize coating and detection antibody concentrations for your specific assay format.
• Given the cross-reactivity with mouse and rat, validate the antibody in the relevant tissue or biological fluid to confirm specificity for your experimental system.
• Note that CFB is a serine protease zymogen; the active enzyme is generated by factor D cleavage, so consider the activation status in your samples and how it may affect antibody recognition.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, research laboratories, and institutes with one‑stop access to high‑quality IVD raw materials, including validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents. For complement factor B (CFB), a key target in complement‑related disease diagnostics, we can support your assay development with sourcing and technical expertise. Whether you need rare‑target raw materials or customized reagent supply, CamelBio bridges the gap from concept to clinic.